Citations

Clear

6411 citation(s) found for "Ma, Christopher".

Inequities in ‘failure to rescue’ for Indigenous Māori after gastrointestinal cancer surgery in New Zealand
Wells, Cameron I. , Wehipeihana, Emma, Varghese, Chris , Paterson, Luke , O’Grady, Gregory , Harmston, Christopher , Bissett, Ian , O'Grady, Gregory , Gurney, Jason , Bissett, Ian , Varghese, Chris , Wells, Cameron , Koea, Jonathan

Mayo Clinic

British Journal of Surgery | July 14, 2025 | Volume: 112 | Issue: 8 | Pages: No page available

10.1093/bjs/znaf161 | PMID 40820525 Get It

Abstract Background Indigenous populations worldwide experience unjust inequities in surgical outcomes. In Aotearoa New Zealand, Indigenous Māori experience poorer health outcomes, including higher rates of postoperative mortality. The aim of this study was to quantify ethnic disparities in ‘failure to rescue’ (FTR), complications, and mortality following gastrointestinal cancer surgery and to analyse trends over time. Methods A retrospective national population-based cohort study of patients undergoing resection for gastrointestinal and hepatopancreatobiliary cancers from 2005 to 2020 was conducted. Self-reported ethnicity data were collected at the time of surgery. The primary outcome was FTR, defined as mortality following a complication within 90 days of surgery. Results In total, 31 185 patients were included; 2479 (7.9%) were Māori, 46.5% were female, and the median age was 71 (interquartile range 62–78) years. Māori patients were younger and had higher levels of socio-economic deprivation and co-morbidity. Māori had higher age-standardized rates of mortality (5.9% versus 3.2%), complications (52.9% versus 42.4%), and FTR (10.8% versus 7.2%), compared with European/Other. Multivariable regression demonstrated higher odds of mortality (adjusted OR (aOR) 1.45 (95% c.i. 1.15–1.82)), complications (aOR 1.30 (95% c.i. 1.17–1.45)), and FTR (aOR 1.29 (95% c.i. 1.01–1.62)) for Māori. Analysis over time showed a significant improvement in risk-adjusted rates of mortality (6.2% in 2005–2008 versus 3.4% in 2017–2020) and FTR (7.3% in 2005–2008 versus 4.0% in 2017–2020) for European/Other, but no change for Māori (rates of mortality were 6.6% in 2005–2008 versus 5.4% in 2017–2020 and rates of FTR were 7.8% in 2005–2008 versus 6.3% in 2017–2020). Conclusion Widening inequities in FTR have worsened disparities in postoperative mortality for Māori patients. ‘Complication rescue’ is a target to reduce inequities and improve perioperative care for Māori patients.
Sequence variability of BamA and FadL candidate vaccinogens suggests divergent evolutionary paths of Treponema pallidum outer membrane proteins
Bettin, Everton B. , Aghakhanian, Farhang , Hennelly, Christopher M. , Chen, Wentao , Davenport, Timothy C. , Hackl, Simon T. , Grassmann, André Alex , Vargas-Cely, Fabio Samir , Silva, Sebastián , Luna, Jonny Alejandro García , Jiang, Yinbo , Yang, Ligang , Zheng, Heping , Pospíšilová, Petra , Šmajs, David , Matoga, Mitch , Hoffman, Irving , Moody, M. Anthony , Salazar, Juan C. , Radolf, Justin D. , Vargas-Cely, Fabio, Šmajs, David , Caimano, Melissa J , Hawley, Kelly L , Radolf, Justin D , Ramirez, Lady Giovanna , Yang, Bin , López‐Medina, Eduardo , Nieselt, Kay , Seña, Arlene C. , Parr, Jonathan B.

Mayo Clinic

Journal of Bacteriology | July 14, 2025 | Volume: 207 | Issue: 8 | Pages: No page available

10.1128/jb.00159-25 | PMID 40802283 Get It

ABSTRACT Knowledge of Treponema pallidum subspecies pallidum ( TPA ) outer membrane protein (OMP) sequence variability is essential for understanding spirochete proliferation within endemic populations as well as the design of a globally effective syphilis vaccine. Our group has identified extracellular loops (ECLs) of TPA BamA (TP0326) and members of the FadL family (TP0548, TP0856, TP0858, TP0859, and TP0865) as potential components of a multivalent vaccine cocktail. As part of a consortium to explore TPA strain diversity, we mapped the variability of BamA and FadL orthologs in 186 TPA strains from Malawi, China, and Colombia onto predicted 3D structures. The 186 genomes fell into eight subclades (five Nichols- and three SS14-lineage) with substantial geographic restriction. Single nucleotide variants accounted for the large majority of proteoforms, with variability notably higher within the Nichols-lineage strains. Most mutations were in regions of the proteins predicted to be extracellular and harboring B cell epitopes. We observed a striking difference in the degree of variability between the six OMPs, suggesting that these proteins are following divergent evolutionary paths. Concatenation of OMP sequences recapitulated the phylogenetic structure of the TPA strains, effectively segregating within clades and largely clustering by subclades. Finally, we noted that BamA and FadL candidate ECL vaccinogens, previously shown to elicit antibodies that kill treponemes during in vitro cultivation, are well conserved. Taken as a whole, our study establishes a structural-phylogenetic approach for analyzing the forces shaping the host-pathogen interface in syphilis within endemic populations while informing the selection of vaccine targets. IMPORTANCE Syphilis remains a major global health concern, reinforcing the need for a safe and effective vaccine. Understanding the variability of TPA OMPs is essential for tracking pathogen evolution and informing vaccine design. Here, we analyzed the variability of six TPA OMPs in 186 strains from Malawi, China, and Colombia, identifying protein-specific evolutionary patterns. Most mutations were localized in extracellular regions and, notably, appeared to correlate with the phylogenetic structure of TPA . Despite OMP heterogeneity, several candidate vaccinogens remained highly conserved, reinforcing their potential as globally effective vaccine targets. Our study establishes a structural-phylogenetic framework for dissecting the forces shaping the host-spirochete interface within endemic populations and provides a foundation for designing a globally effective syphilis vaccine.
Association of Diuretic Dosage With Outcomes in Patients With Hemodynamically Significant Isolated Tricuspid Valve Regurgitation
Anand, Vidhu , Scott, Christopher G. , Ali, Khaled A., Nkomo, Vuyisile T. , Thaden, Jeremy J. , Kane, Garvan C. , Borgeson, Daniel D., Borlaug, Barry A. , Pislaru, Cristina , Eleid, Mackram F. , Ali, Khaled, Crestanello, Juan A , Pellikka, Patricia A , Sabbah, Michael S. , Nkomo, Vuyisile T , Scott, Christopher , Borlaug, Barry A , Pislaru, Cristina , Ali, Khaled, Crestanello, Juan A. , Pellikka, Patricia A. , Pislaru, Sorin V.

Mayo Clinic

Journal of the American Heart Association | July 14, 2025 | Volume: 14 | Issue: 14 | Pages: No page available

10.1161/jaha.124.039989 | PMID 40654247 Get It

Background Tricuspid valve surgery is recommended for severe isolated tricuspid regurgitation (TR) if symptoms persist despite optimal medical therapy. The definition of optimal therapy for TR is unclear beyond managing underlying conditions. Diuretics are the primary treatment for volume retention in TR, but it is unknown whether a “safe diuretic dose” exists for conservative management. We sought to evaluate the association between diuretic dose and outcomes. Methods Adult patients with ≥moderate–severe isolated TR were retrospectively identified from echocardiographic reports. Clinical and echocardiographic data were extracted from electronic medical records and manually reviewed. The primary end point was all‐cause mortality. Loop diuretic doses were converted to furosemide equivalent and categorized into 4 groups: <40 mg, 40 to 79 mg, 80 to 159 mg, and ≥160 mg daily. Results Of 1302 patients (age 72±13 years, 60% female), 565 (43%) had moderate–severe TR and 737 (57%) had severe TR. Median follow‐up was 8.7 (1.4, 14.0) years. Comorbidities increased with higher diuretic doses. A linear relationship between diuretic dose and mortality was observed in spline‐curve analysis. Hazard ratios (and CIs) for mortality adjusted for age, sex, coronary disease, chronic kidney disease, mild pulmonary hypertension, and New York Heart Association III/IV symptoms were 1.21 (0.96–1.53) ( P =0.12) for <40 mg, 1.50 (1.23–1.82) ( P <0.001) for 40 to 79 mg, 1.86 (1.46–2.37) ( P <0.001) for 80 to 159 mg, and 2.90 (2.18–3.88) ( P <0.001) for ≥160 mg furosemide equivalent. Any diuretic dose was associated with significant symptoms (New York Heart Association III–IV), with more patients experiencing symptoms at higher doses. Conclusion A daily loop diuretic dose ≥40 mg furosemide equivalent is associated with increased mortality and greater symptom severity in patients with TR.
Space Oncology: A Comprehensive Scoping Review
Niknam, Nafise , Akbarialiabad, Hossein , Kouhanjani, Mohsen Farjoud , Varghese, Lydia Johnson Kolaparambil , González, Amy Berrington de , Melin, M. Mark , Shafie’ei, Mohammad , Mousavi, Seyedeh Maryam , Hosseini, Seyed Ali , Taha, Seyed Reza , Grada, Ayman , Akbari, Zahra , Jokar-Derisi, Armita , Jurga, Marta , Das, Saswati , D’Urbano, Jessica , Hakim, Gabriella, Sadeghian, Najmeh , Tarbox, Michelle , West, Cameron , Hosseini, Seyed Hossein , Squire, Timothy , Christiansen, Rowena , Melin, Matthew M , Farjoud Kouhanjani, Mohsen , Kolaparambil Varghese, Lydia Johnson , Russomano, Thais , Murrell, D F , Leachman, Sancy A , Akbari, Zahra , Derisi, Armita Jokar , Das, Saswati , D'Urbano, Jessica , Hakim, Gabriella , Sadeghian, Najmeh , Paydar, Shahram , Tarbox, Michelle , West, Cameron , Ghorashi, Seyyed Mojtaba , Hosseini, Seyed Hossein , Squire, Timothy , Christiansen, Rowena , Berrington de Gonzalez, Amy , Leachman, Sancy A. , Kumar, Ajay , Bunick, Christopher G.

Mayo Clinic

Wilderness & Environmental Medicine | July 14, 2025 | Volume: 36 | Issue: 1_suppl | Pages: No page available

10.1177/10806032251349442 | PMID 40653854 Get It

Space exploration exposes astronauts to unique conditions such as microgravity and space radiation, potentially influencing gene expression and triggering carcinogenesis. Paradoxically, these extreme environments could uncover other pro-treatment aspects of cancer biology. Despite numerous reviews addressing these aspects in isolation, a comprehensive synthesis of the effects of space stressors on cancer development is incomplete. This scoping review aims to provide a holistic perspective on the influence of spaceflight and associated stressors—including gravitation (hyper- and microgravity), radiation, and vibration—on the potential for cancer development and altered cellular mechanisms. We adhered to the PRISMA-ScR checklist for our review. A multitiered search strategy was employed in English, starting with a preliminary keyword identification in Google Scholar and PubMed. Subsequently, the main search was conducted across five databases—Cochrane, Embase, PubMed, Scopus, and Web of Science—until 22 February 2024. All included studies were thoroughly assessed by two independent reviewers. Of the 15,553 identified articles, 158 were deemed eligible. The majority (92%) were experimental studies, predominantly cell-based (74.17%). Breast (15.19%), thyroid (13.92%), and hematopoietic (11.40%) cancers were the most frequently examined. Spaceflight stressors could affect different biological systems variably, with microgravity impacting spatial growth and metastasis, and cosmic radiation exerting both tumor-suppressive and mutagenic effects. Our findings highlight the need for large-scale, prolonged analog studies mimicking space conditions to enhance mission safety and shed light on the nuanced effects of space stressors on cancer. Additionally, further extensive studies need to be performed in the true weightlessness of spaceflight, both animal-based and on human tissue (cell cultures and potentially whole perfusion organ models), in addition to crew pre/intra/post-flight long-duration evaluations. Furthermore, this unique research avenue may reveal cancer cell sensitivities to these stressors, opening new pathways for innovative therapeutic strategies in cancer treatment.
E-059 Influence of race on extended length of stay following mechanical thrombectomy for anterior circulation stroke
Koo, A, Johnson, Scott, Starke, R, Welch, Babu G. , Rivet, Dennis J. , Graffeo, Christopher S. , Klopfenstein, Jeffrey D., Sahlein, D, Eshraghi, Sheila, Altschul, D, Alaraj, A, Davies, Jason M., Raper, D, Park, M , Malek, Adel M. , Monteith, Stephen J., Eckardt, Glenn S., Beaty, N, Schirmer, C, Arthur, A, Wolfe, S, Chen, C, Church, E, Dornbos, D, Chu, T, Johnson, S, Starke, R, Altschul, David , Ringer, Andrew J. , Hoh, Brian L. , Alaraj, Ali , Mocco, J , Grande, Andrew Walker , Eckardt, G, Beaty, Narlin Bennet , Schirmer, Clemens M., Arthur, A, Dornbos, David

Mayo Clinic

SNIS 22nd annual meeting electronic poster abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A132.1-A132

10.1136/jnis-2025-snis.175 Get It

The Geriatric Emergency Care Applied Research Standardization Study ( GEARSS ): An Observational Study of Older Emergency Department Patients
Hwang, Ula , Sifnugel, Natalia, Cohen, Inessa , Han, Ling, Araujo, Katy, Bianco, Luann, Capelli, Sandra, Cruz, Daniel S. , Fishman, Ivy L., Gipson, Katrina, Hung, William W. , Kang, Raymond , Lockhart, Mechelle, Ohuabunwa, Ugochi , Ottilie‐Kovelman, Sierra, Partridge, Caitlin, Platts‐Mills, Timothy F. , Sandoval, Jacqueline , Taylor, Zachary , Tomasino, Debra F. , Vaughan, Camille P. , Tomasino, Debra F , Vaughan, Camille P , Hwang, Ula , Brandt, Cynthia , Carpenter, Christopher R. , Dresden, Scott M. , Hastings, Susan N. , Meeker, Daniella , Taylor, Zachary

Mayo Clinic

Academic Emergency Medicine | July 12, 2025 | Volume: 33 | Issue: 1 | Pages: No page available

10.1111/acem.70101 | PMID 40650481 Get It

ABSTRACT Objectives Multicenter research of geriatric emergency department (GED) care remains limited. Our objectives were to: 1. Prospectively collect data prioritized by the Geriatric Emergency care Applied Research (GEAR) network, a transdisciplinary taskforce for GED care, and create a multicenter GED research repository of prospective and electronic health record (EHR) data, 2. Assess concordance between prospective and EHR data. Methods The GEAR Standardization Study (GEARSS) is a multicenter, prospective study of older emergency department (ED) patients (65+) focusing on the 4Ms of age‐friendly care (mobility, medication safety, mentation, what matters) and elder mistreatment. Demographic and clinical data were collected via interviews by trained research assistants (RA) on Days 0, 4, 30, and 90 and linked to EHR. Prevalence of chronic comorbidities and incident delirium were measured and reported using descriptive statistics. Prospective and EHR data concordance was assessed with Cohen's Kappa. Results 999 participants were recruited from 5 EDs (3/25/2021–6/30/2022) across 3 institutions: Grady Health System, Northwestern Memorial Hospital, and Yale New Haven Health. The cohort was 57.0% female, 55.2% White, 39.1% Black, and 3.4% Hispanic, and the mean age was 75.1 years. For rheumatologic disease, peptic ulcer disease, diabetes, renal disease, and cancer, prevalence differed between prospective and EHR data by > 10%. About two‐thirds of participants were at risk for falls. Concordance between prospective and EHR data was good for ethnicity ( K = 0.73); excellent for sex ( K = 1.00), age ( K = 1.00), and race ( K = 0.98); fair for disposition ( K = 0.53); slight for ED observation status ( K = 0.33) and dementia diagnosis ( K = 0.24); poor for delirium presence ( K = 0.07). Conclusion In GEARSS, demographic variables aligned strongly between prospective and EHR data, while diagnosis, disposition, and mentation factors did not. This multicenter data source provides preliminary findings for common geriatric syndromes and conditions. Choice of measures using these data should be driven by GED research questions.
Novel approach to improving teamwork in healthcare
Collura, Christopher A. , Misgen, Megan M., Stetson, Raymond C. , Mavis, Stephanie C. , Omdahl, Tami K, Reeve, Claire E, Colby, Christopher E. , Brumbaugh, Jane E.

Mayo Clinic

BMJ Leader | July 10, 2025 | Volume: 9 | Issue: 4 | Pages: 467-469

10.1136/leader-2024-001159 | PMID 40639938 Get It

Background Excellence in healthcare delivery is dependent on individuals working together on a team. Objective We sought to enhance team performance by partnering with human resources (HR) to identify opportunities unrecognised by unit leadership. Methods 100 individuals representing a cross-section of the multidisciplinary team participated in an interview focused on teamwork conducted by an HR representative. Action plans were then developed and implemented. Press Ganey Survey results for the question, “Staff worked together to care for you/your baby?” were tracked to assess patient perception of teamwork. Results Between 2022 and 2024, we observed improvement in the per cent of patients who assigned the highest rating of teamwork, culminating in 100% of patients reporting the highest score in the final quarter. Conclusion The model of HR facilitated discussions with work unit team members identified barriers to optimal teamwork, led to the implementation of action plans and resulted in an improvement in our teamwork rating by patients.
NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025
Haddad, Robert I. , Bischoff, Lindsay , Applewhite, Megan K. , Bernet, Victor , Blomain, Erik , Brito, Maria , Busaidy, Naifa L. , Campbell, Michael J. , DeLozier, Olivia M. , Duh, Quan‐Yang , Ehya, Hormoz, Grady, Erin C., Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Lorch, Jochen H. , Mandel, Susan J., Mydlarz, Wojciech K. , Raeburn, Christopher D., Rezaee, Rod , Ritter, Hadley E., Roth, Mara Y. , Salgado, Sarimar Agosto , Scheri, Randall P., Sipos, Jennifer A. , Wirth, Lori J. , Darlow, Susan, Cassara, Carly J., Sliker, Bailee , Haddad, Robert , Guo, Theresa , Haymart, Megan R. , Kotwal, Anupam , Markovina, Stephanie T. , Nabell, Lisle M. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Worden, Francis P. , Yeh, Michael W.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available

10.6004/jnccn.2025.0033 | PMID 40639400 Get It

The NCCN Guidelines for Thyroid Carcinoma address the management of different types of thyroid carcinoma, including papillary, follicular, oncocytic, medullary, and anaplastic carcinoma. The NCCN Thyroid Carcinoma Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights focus on the panel’s most recent recommendations regarding systemic therapies for thyroid carcinoma as well as the supporting clinical data.
Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Swarm, Robert A., Youngwerth, Jeanie, Anițescu, Magdalena , Are, Madhuri , Buga, Sorin , Butler, Taylor, Cleary, James F. , Copenhaver, David, Coyne, Christopher , Craig, David S., Finnes, Heidi D. , Greenlee, Heather , Gupta, Mona, Hansen, Eric, Javed, Saba , Kandil, Enas , Mackey, Sean , McGrath, Kathryn, Moryl, Natalie , Nesbit, Suzanne , Noonan, Michael , Norris, Joseph, Pršić, Elizabeth , Rabow, Michael W. , Rickerson, Elizabeth , Sindt, Jill E. , Vorenkamp, Kevin E. , Cunningham, Rebecca, Gurski, Lisa A., Jones, Frankie, Finnes, Heidi, Agne, Julia L. , Butler, Taylor, Chwistek, Marcin , Gupta, Mona, Javed, Saba , McDonald, Andrew, Noonan, Michael, Paice, Judith A. , SMITH, MICHAEL D. , Bruce, Justine Y. , Yoo, Sun

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available

10.6004/jnccn.2025.0032 | PMID 40639401 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain provide recommendations for the comprehensive management of pain in patients with cancer. This article will focus on methods for screening for pain, safe and appropriate prescription of opioid and miscellaneous analgesics, and the optimization of nonpharmacologic interventions including integrative and interventional strategies for treatment of cancer-related pain. Additionally, the NCCN Guidelines discuss methods for the safe reduction of opioids when appropriate, as well as techniques for encouraging the judicious use of opioids. The complete version of the NCCN Guidelines for Adult Cancer Pain addresses additional issues that are not covered here, including management of pain during a pain crisis, management of procedure-related pain and anxiety, pain management for cancer survivors, and the use of nonopioid and adjuvant analgesics for cancer-related pain.
Response to Biologics in Patients With Early-Onset Treatment-Naïve Metastatic Colorectal Cancer—An Aide et Recherche en Cancérologie Digestive Database Analysis
Jin, Zhaohui , Hubbard, Joleen M. , Eng, Cathy , Lieu, Christopher H. , Douillard, Jean‐Yves , Adams, Richard , Maughan, Tim , Cutsem, Eric Van , Venook, Alan P. , Lenz, Heinz‐Josef , Heinemann, Volker , Schmoll, H.J.E-V., Fuchs, Charles S. , Hecht, J. Randolph , Punt, Cornelis J. A. , Bokemeyer, Carsten , Gramont, Aimery de , Venook, Alan P , Maughan, Timothy S , Hubbard, Joleen , Adams, Richard , Van Cutsem, Eric , Lieu, Christopher , Jin, Zhaohui , Eng, Cathy , Dixon, Jesse G. , Stintzing, Sebastian , Saltz, Leonard B. , Falcone, Alfredo , Díaz‐Rubio, Eduardo , Punt, Cornelis J.A. , Tebbutt, Niall C. , Chibaudel, Benoist , Zalcberg, John , Yoshino, Takayuki , Shi, Qian

Mayo Clinic

JCO Oncology Advances | July 9, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-24-00080 Get It

PURPOSE Colorectal cancer (CRC) incidence and mortality have decreased since the 1970s, but the incidence in young adults (<50 years, named early-onset CRC [eoCRC]) has been increasing. PATIENTS AND METHODS Individual patient data on 13,365 patients with metastatic CRC enrolled between 2000 and 2012 in 17 first-line randomized trials in the Aide et Recherche en Cancérologie Digestive database were pooled. The distribution of demographics, clinicopathologic features, biomarkers, and outcome data were summarized and compared by age groups. Progression-free survival (PFS) and overall survival (OS) were assessed by Kaplan-Meier curves and Cox models stratified by treatment arms within studies, adjusting for potential confounders. Predictive value of age group on clinical outcomes was evaluated by testing interaction effect between treatment and age variables. RESULTS Overall, 2,045 patients with eoCRC (median age, 42.5) and 11,320 patients with average-onset CRC (aoCRC; median age, 63.8) were included in this analysis. Within the eoCRC population, treatment with bevacizumab in addition to chemotherapy improved PFS (9.9 v 6.8 months; hazard ratio [HR], 0.66 [95% CI, 0.54 to 0.80]; P < .0001), which was similar to the findings in aoCRC population (9.4 v 7.3 months; HR, 0.73 [95% CI, 0.67 to 0.80]; P < .001; interaction P = .5415). However, epithelial growth factor receptor inhibitor (EGFRi) did not improve PFS in RAS wild-type (WT) patients with eoCRC who had left-sided primary tumors (8.3 v 8.9 months; HR, 1.20 [95% CI, 0.81 to 1.77]; P = .36), whereas EGFRi significantly improved PFS in the aoCRC population (9.9 v 8.5 months; HR, 0.74 [95% CI, 0.64 to 0.86]; P < .0001; interaction P = .083). CONCLUSION Treatment-naïve patients with metastatic eoCRC appear to derive similar benefit from bevacizumab as patients with aoCRC. However, patients with eoCRC with left-sided RAS/RAF WT tumors did not appear to derive benefit from first-line EGFRi.